Compare MGIH & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIH | PASG |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | 27 |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 19.2M |
| IPO Year | 2022 | 2020 |
| Metric | MGIH | PASG |
|---|---|---|
| Price | $1.58 | $6.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 39.8K | 37.4K |
| Earning Date | 10-28-2025 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.35 |
| 52 Week High | $4.84 | $20.00 |
| Indicator | MGIH | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 58.31 |
| Support Level | $1.40 | $6.04 |
| Resistance Level | $1.82 | $8.94 |
| Average True Range (ATR) | 0.14 | 0.46 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 49.99 | 96.62 |
Millennium Group International Holdings Ltd supplies paper-based packaging solutions, including inner packaging boxes produced with offset or flexo printing and outer corrugated boxes used for transportation, storage, pallets, and point-of-purchase displays. The company manufactures corrugated products of different sizes, shapes, thicknesses, and strengths according to customer specifications. It also operates a supply chain management business in Vietnam to service international clients who source their packaging needs from Vietnam and other ASEAN countries. The corrugated paper is durable, versatile, economical, and lightweight.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.